{
    "clinical_study": {
        "@rank": "63612", 
        "arm_group": [
            {
                "arm_group_label": "HPV-1 Group", 
                "description": "Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan."
            }, 
            {
                "arm_group_label": "HPV-2 Group", 
                "description": "Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan."
            }
        ], 
        "brief_summary": {
            "textblock": "This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and\n      the quadrivalent HPV vaccine (HPV-2)."
        }, 
        "brief_title": "Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine", 
        "completion_date": {
            "#text": "February 2010", 
            "@type": "Actual"
        }, 
        "condition": "Human Papillomavirus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study uses a prevalence-based model (by using efficacy data from each vaccine's\n      respective trials and published cost data for Taiwan) which estimates the differences in\n      lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective\n      prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated).\n      It also analyses costs from a societal perspective."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan\n             (hypothetical group).\n\n        Exclusion Criteria:\n\n          -  Not applicable."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hypothetical group of women vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan."
            }
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702337", 
            "org_study_id": "114420"
        }, 
        "intervention": {
            "arm_group_label": [
                "HPV-2 Group", 
                "HPV-1 Group"
            ], 
            "description": "Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).", 
            "intervention_name": "Prevalence-based model", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gardasil", 
            "Prevalence-model", 
            "Cervarix", 
            "economic", 
            "health"
        ], 
        "lastchanged_date": "October 4, 2012", 
        "number_of_groups": "2", 
        "official_title": "Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Food and Drug Administration, Department of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Annual number of lesions prevented by each vaccine", 
                "safety_issue": "No", 
                "time_frame": "Over a one-year period"
            }, 
            {
                "measure": "Lesion related total cost averted by each vaccine", 
                "safety_issue": "No", 
                "time_frame": "Over a one-year period"
            }, 
            {
                "measure": "Additional costs averted by HPV-1 vaccine compared to HPV-2 vaccine", 
                "safety_issue": "No", 
                "time_frame": "Over a one-year period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702337"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2010", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}